The company plans to increase its presence in Kuwait to reach a team of 25-30 employees  

Kuwait, July 10, 2016:  Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced today that it has recently opened its new office in the State of Kuwait. The opening ceremony was held in YIACO Medical Company’s (YIACO) headquarters, in Salmiya, and where senior representatives from both companies were present. 

YIACO’s management team included Dr. Bader Altraiji, Chief Executive Officer; Dr. Mohamed Barham, Chief Operational Officer; Dr. Fawaz Al Omi, Chief Communications Officer and Dr. Abdulla Al Bader, Pharmaceutical and Healthcare Manager. Representing Boehringer Ingelheim were Mazen Bachir, Country Manager – Gulf and Iran and the company’s wider team in Kuwait.

During the opening ceremony, Mazen Bachir said, “Kuwait is an important market for Boehringer Ingelheim’s operations in the region, and we are proud to collaborate with our agent, YIACO, to deliver patient focused solutions.  Our commitment to excellence and comprehensive understanding of patient needs in Kuwait makes us confident to deliver value across a number of therapeutic areas including diabetes, respiratory, cardiovascular diseases as well as lung cancer.”

“Our aim is to continue growing our presence in Kuwait to reach a team of 25-30 employees while increasing our overall business in the coming few years,” added Bachir.

Moreover, Dr. Bader Al Traji, Chief Executive Officer of YIACO also said, “The continued growth of Kuwait’s population and rise in conditions such as diabetes and obesity has prompted more demands for a stronger healthcare offering. We are proud to partner with Boehringer Ingelheim to expand their presence across the country with an underlying objective of further enhancing community wellbeing.”

Boehringer Ingelheim is committed to research into patient populations to improve the overall understanding of their conditions and patient experiences.